Business Context and Reporting Period
This Form 8-K filing by Community Health Systems, Inc. (CHS) reports corporate governance changes effective September 14, 2016, with retroactive application to September 1, 2016. The filing details the appointment of new executive leadership and the approval of revised compensation arrangements for a Named Executive Officer.
Key Financial Metrics
The filing does not report consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics for the company. It focuses exclusively on executive compensation figures:
- Base Salary: Tim L. Hingtgen's annualized base salary was increased to $725,000.
- Maximum Incentive Opportunity: 200% of base salary for the period September 1, 2016, through December 31, 2016.
- Equity Grant: 50,000 time-based restricted shares granted to Mr. Hingtgen, effective October 1, 2016.
Material Changes Versus Prior Period
The primary material change is the restructuring of the executive leadership team and associated compensation plans:
- Leadership Transition: Tim L. Hingtgen was appointed President and Chief Operating Officer (COO), replacing David L. Miller in that role.
- Role Change: David L. Miller, formerly President and COO, was appointed Executive Vice President and Special Advisor to the CEO as he prepares to retire at the end of 2016.
- Compensation Revision: Mr. Hingtgen's incentive plan was revised to align with his new COO responsibilities, shifting weight toward Company EBITDA (125% opportunity) and including specific non-financial performance criteria.
Guidance, Outlook, and Management Commentary
The filing references the company's fiscal year 2016 guidance for volume, revenue, and earnings growth, which was previously reported in an 8-K filed on August 2, 2016. This guidance serves as a performance metric for Mr. Hingtgen's incentive compensation.
Compensation Structure Details:
- Performance Goals: The incentive plan is weighted toward Company EBITDA (125%), Continuing Operations EPS (20%), Net Revenues (20%), Performance Improvements (25%), and Overachievement of Company Goals (10%).
- Non-Financial Criteria: Includes physician recruitment, capital budget adherence, clinical compliance, and meeting fiscal guidance.
- Equity Vesting: The 50,000 restricted shares vest in equal one-third increments over three years, with acceleration provisions for death, disability, change in control, or termination without cause.
Important Facts for Investor Verification
- Verify the specific fiscal year 2016 guidance targets for volume, revenue, and earnings referenced in the August 2, 2016 filing to assess the difficulty of the performance metrics tied to executive compensation.
- Confirm the total number of shares outstanding and the impact of the 50,000 restricted share grant on dilution.
- Monitor the transition period between Mr. Miller and Mr. Hingtgen to ensure operational stability across the five operating divisions.
- Note that Mr. Hingtgen receives no direct compensation for his services as an officer of the parent company, as he is employed by the wholly-owned subsidiary CHSPSC, LLC.